Celecoxib up-regulates the expression of the ζ chain of T cell receptor complex in tumor-infiltrating lymphocytes in human cervical cancer

Clinical Cancer Research

Volumn 12, Issue 7 I, 2006, Pages 2055-2060

  Ferrandina, Gabriella ^a   Ranelletti, Franco Oreste ^a   Legge, Francesco ^a   Salutari, Vanda ^a   Martinelli, Enrica ^a   Fattorossi, Andrea ^a   Lorusso, Domenica ^b   Zannoni, Gianfranco ^a   Vellone, Valerio ^a   Paglia, Amelia ^a   Scambia, Giovanni ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 2; CYTOKINE; ENDOSTATIN; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; KI 67 ANTIGEN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ZETA CHAIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG TOLERANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; RECEPTOR UPREGULATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; CYTOKINES; ENDOSTATINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; MIDDLE AGED; PATIENT COMPLIANCE; PYRAZOLES; RECEPTORS, ANTIGEN, T-CELL; SULFONAMIDES; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646267954     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2530     Document Type: Article

References (42)

1. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB. Cyclooxygenase-2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-51.
2. Dannemberg AJ, Subbamaraiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell 2003;4:431-6.
3. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-72.
4. Nithipathikom K, Isbell MA, Lindholm PF, Kaydacsy-Balla A, Kaul S, Campbell WB. Requirement of cyclooxygenase-2 expression and prostaglandins for human prostate cancer cell invasion. Clin Exp Metastasis 2002;19:593-601.
5. Stolina M, Sharma S, Lin Y, et al. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 2000;164:361-70.
6. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-5.
7. Ferrandina G, Lauriola L, Distefano MG, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002;20:973-81.
8. Ferrandina G, Lauriola L, Zannoni GF, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002;13:1205-11.
9. Ferrandina G, Ranelletti FO, Legge F, et al. Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical. Clin Cancer Res 2004;10:3117-23.
10. Ferrandina G, Lauriola L, Zannoni GF, et al. Expression of cyclooxygenase-2 (COX-2) in tumor and stroma compartments in cervical cancer: clinical implications. Br J Cancer 2002;87:1145-52.
11. Distefano M, Ferrandina G, Smaniotto D, et al. Concomitant radiochemotherapy plus surgery in locally advanced cervical cancer: update of clinical outcome and cyclooxygenase-2 as predictor of treatment susceptibility. Oncology 2004;67:103-11.
12. Benitez-Bribiesca L, Wong A, Utrera D, Castellanos E. The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix. J Histochem Cytochem 2001;49:1061-2.
13. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
14. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib administered during different stages of carcinogenesis. Cancer Res 2000;60:293-7.
15. Kaur S, Khamnehey N, Iravani M, Namburu SS, Lin O, Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase-2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 2002;123:60-7.
16. Ferrandina G, Ranelletti FO, Legge F, et al. Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related markers and microvessel density in cervical cancer: a pilot study. Clin Cancer Res 2003;9:4324-31.
17. Lang S, Lauffler L, Clausen C, et al. Impaired monocyte function in cancer patients: restoration with a cyclooxygenase-2 inhibitor. FASEB J 2003;17:286-8.
18. Sharma S, Stolina M, Yang S, et al. Tumor cyclooxygenase-2 dependent suppression of dendritic cell function. Clin Cancer Res 2003;9:961-8.
19. Sharma S, Yang SC, Zhu L, et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005;65:5211-20.
20. Mao JT, Roth MD, Serio KJ, et al. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. Clin Cancer Res 2003;9:5835-41.
21. Whiteside TL. Down-regulation of ζ-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004;53:865-78.
22. Mulder WMC, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ. T cell receptor-ζ and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 1997;40:113-9.
23. de Gruijl TD, Bontkes HJ, Peccatori F, et al. Expression of CD3-ζ on T-cells in primary cervical carcinoma and in metastasis-positive and -negative pelvic lymph nodes. Br J Cancer 1999;79:1127-32.
24. Riccobon A, Gunelli R, Ridolfi R, et al. Immunosuppression in renal cancer: differential expression of signal transduction molecules in tumor-infiltrating, near-tumor tissue, and peripheral blood lymphocytes. Cancer Invest 2004;22:871-7.
25. Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002;16:56-60.
26. Anderson P, Blue ML, O'Brien C, Schlossman SF. Monoclonal antibodies reactive with the T-cell receptor ζ chain: production and characterization using a new method. J Immunol 1989;143:1899-904.
27. West CM, Cooper RA, Loncaster JA, Wilks DP, Bromley M. Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res 2001;61:2907-10.
28. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137-45.
29. Kuss I, Saito T, Johnson JT, Whiteside TL. Clinical significance of decreased ζ chain expression in peripheral blood lymphocytes of patients with head and neck cancer. Clin Cancer Res 1999;5:329-34.
30. Rabinovitch H, Banks M, Reicher TE, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin therapy. Clin Cancer Res 1996;2:1263-74.
31. Matsuda M, Petersson M, Lenke R, et al. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of disease. Int J Cancer 1995;61:765-72.
32. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998;58:5344-7.
33. Yang L, Yamagata N, Yadav R, et al. Cancer associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 2003;111:727-35.
34. De Long P, Tanaka T, Kruklitis R, et al. Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 2003;63:7845-52.
35. Franco J, Ghosh P, Wiltrout R, et al. Partial degradation of Tcell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor bearing mice. Cancer Res 1995;55:3840-6
36. Kono K, Salazar-Onfray F, Pettersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing ζ molecules and inhibits tumor-specific T cell and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996;26:1308-13.
37. Kim JW, Wieckowski E, Taylor D, Reichert T, Whiteside T. FasL-containing microvesicles in the circulation of patients with cancer induce apoptosis of activated T lymphocytes. Abstr J Immunother 2003;26:344.
38. Kiessling R, Kono K, Petersson M, Wasserman K. Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules. Springer Semin Immunopathol 1996;18:227-42.
39. Healy CG, Simons JW, Carducci MA, et al. Impaired expression and function of signal-transducing ζ chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998;32:109-19.
40. Taylor DD, Bender DP, Gercel-Taylor C, Stanson J, Whiteside TL. Modulation of TcR/CD3 ζ chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer 2001;84:1624-9.
41. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclooxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005;7:422-35.
42. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: shifting the angiogenic balance. Proc Natl Acad Sci U S A 2002;99:13243-7